MicroRNAs (miRNAs) are small endogenous RNAs approximately 22 nucleotides involved in the regulation of several cellular metabolisms including cholesterol metabolism. The objective of this study was to measure miRNAs 33a and 33b in type 2 diabetics to evaluate their impact on the lipids levels and prevalence of dyslipidemia. The study population profile was 45 subjects including 30 type 2 diabetic patients and 15 healthy controls. The lipids tests were performed using an automated Spintech 240 Biolis analyzer and the microRNAs (33a and 33b) by applied biosystems 7500 Fast Real Time PCR System using the TaqMan® MicroRNA Assay kit. The prevalence of dyslipidemia was higher in miRNA-33a positive subjects than miRNA-33a negative (p <0.0001). The prevalence of dyslipidemia was however not significant between miRNA-33b positive and miRNA-33b negative. A comparison between miRNA-33a positive and miRNA-33b positive showed a significant increase of dyslipidemia in miRNA-33a positive than in miRNA-33b positive subjects. The dyslipidemic types in miRNA-33a positive diabetics were 90% hypercholesterolemia, 88% LDLC increase and 83.33% HDLC decrease. The measurement of the HDLC subclasses showed 82.6% HDL2C decrease and 90.91% HDL3C increase. The HDL3C level increased in 100% of non hypertensive diabetics versus 46.67% in hypertensive diabetics (p=0.003). The increase of HDL3C was 90.9% in miRNA33a positive subjects versus 54.5% in miRNA33b positive subjects (p <0.006). The study therefore confirms the relationship between the presence of microRNAs 33a and increased cardiovascular risk. The results showed a role of microRNA-33a on the increase of HDL3C which has a weak atheroprotective role compared to HDL2C. This observation suggests that the research on drugs able to increase the HDLC level based on microRNA regulation should target the stimulation of HDL2C synthesis.
| Published in | Advances in Biochemistry (Volume 7, Issue 4) |
| DOI | 10.11648/j.ab.20190704.11 |
| Page(s) | 71-76 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2020. Published by Science Publishing Group |
Type 2 Diabetes, miRNA-33a / b, Dyslipidemia, Ouagadougou
| [1] | Rotllan N, Fernández-Hernando C. MicroRNA Regulation of Cholesterol Metabolism. Cholesterol. 2012: 847849. doi: 10.1155/2012/847849. |
| [2] | Reddy LL, Shah SAV, Ponde CK, Rajani RM, Ashavaid TF. Circulating miRNA-33: a potential biomarker in patients with coronary artery disease. Biomarkers. 2019 Feb; 24 (1): 36-42. doi: 10.1080/1354750X.2018.1501760. |
| [3] | Näär AM. miR-33: A Metabolic Conundrum. Trends Endocrinol Metab. 2018 Oct; 29 (10): 667-668. doi: 10.1016/j.tem.2018.04.004. |
| [4] | Shao F, Wang X, Yu J, Shen K, Qi C, Gu Z. Expression of miR-33 from an SREBP2 intron inhibits the expression of the fatty acid oxidation-regulatory genes CROT and HADHB in chicken liver. Br Poult Sci. 2019 Apr; 60 (2): 115-124. doi: 10.1080/00071668.2018.1564242. |
| [5] | Sun Y, Zhang D, Liu X, Li X, Liu F, Yu Y, Jia S, Zhou Y, Zhao Y.] Endoplasmic Reticulum Stress Affects Lipid Metabolism in Atherosclerosis Via CHOP Activation and Over-Expression of miR-33. Cell Physiol Biochem. 2018; 48 (5): 1995-2010. doi: 10.1159/000492522. |
| [6] | Alice T. C. R. Kiba Koumaré, Absetou Guira, André Samandoulougou, Elie Kabré, Issaka Sondé, Talkmore Maruta, Jacques Simporé and Jean Sakandé. Plasma lipid profile including the high density lipoprotein (HDL) subclasses in hypertensive patients in Ouagadougou, Burkina Faso. Afr. J. Biochem. Res. 2015, 9 (3): 47-54, DOI: 10.5897/AJBR2015.0825. |
| [7] | Alice TCR Kiba Koumaré, Assana Bouda, Hervé Tiénon, Elie Kabré, Issaka Sondé, Talkmore Maruta, Jacques Simporé and Jean Sakandé. Measurement of Cholesterol Sub-Fractions, High Density Lipoprotein 2 and High Density Lipoprotein 3 in Type 2 Diabetes Mellitus Patients in Burkina Faso (West Africa). Am. J. Biochem. Mol. Biol., 2015, ISSN 2150-4210 DOI: 10.3923/ajbmb.2015. |
| [8] | Jomard A, Osto E Metabolism and Function of High-Density Lipoproteins (HDL). Praxis. 2019; 108 (7): 477-486. doi: 10.1024/1661-8157/a003241. |
| [9] | Hirano, T., K. Nohtomi, S. Koba, A. Muroi and Y. Ito, 2008. A simple and precise method for measuring HDL-cholesterol subfractions by a single precipitation followed by homogenous HDL-cholesterol assay. J. Lipid Res., 49: 1130-1136. |
| [10] | Srisawasdi P, Chaloeysup S, Teerajetgul Y, Pocathikorn A, Sukasem C, Vanavanan S, Kroll MH (2011). Estimation of plasma small dense LDL cholesterol from classic lipid measures. Am. J. Clin. Pathol. 136 (1): 20-9. http://dx.doi.org/10.1309/AJCPLHJBGG9L3ILS |
| [11] | Koumaré Kiba ATCR, Sakandé LPL, Kabré E, Sondé I, Simporé J, Sakandé J (2015) Reference Ranges of Cholesterol Sub-Fractions in Random Healthy Adults in Ouagadougou, Burkina Faso. PLoS ONE 10 (1): e0116420. doi: 10.1371/journal. pone.0116420. |
| [12] | Kuwabara Y, Ono K, Horie T, Nishi H, Nagao K, Kinoshita M, et al. Increased microRNA-1 and microRNA-133a levels in serum of pa- tients with cardiovascular disease indicate myocardial damage. Circ Cardiovasc Genet 2011; 4: 446-454. |
| [13] | Widera C, Gupta SK, Lorenzen JM, Bang C, Bauersachs J, Bethmann K, et al. Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome. J Mol Cell Cardiol 2011; 51: 872-875. |
| [14] | Fichtlscherer S, De Rosa S, Fox H, Schwietz T, Fischer A, Liebetrau C, et al. Circulating microRNAs in patients with coronary artery disease. Circ Res 2010; 107: 677-684. |
| [15] | Tijsen AJ, Creemers EE, Moerland PD, de Windt LJ, van der Wal AC, Kok WE, et al. Mir423-5p as a circulating biomarker for heart failure. Circ Res 2010; 106: 1035-1039. |
| [16] | Li S, Zhu J, Zhang W, Chen Y, Zhang K, Popescu LM, et al. Signa- ture microRNA expression profile of essential hypertension and its novel link to human cytomegalovirus infection. Circulation 2011; 124: 175-184. |
| [17] | Tan KS, Armugam A, Sepramaniam S, Lim KY, Setyowati KD, Wang CW, et al. Expression profile of microRNAs in young stroke patients. PLoS One 2009; 4: e7689, doi: 10.1371/journal.pone.0007689. |
| [18] | Ouimet M, Hennessy EJ, van Solingen C, Koelwyn GJ, Hussein MA, Ramkhelawon B, Rayner KJ, Temel RE, Perisic L, Hedin U, Maegdefessel L, Garabedian MJ, Holdt LM, Teupser D, Moore KJ. miRNA Targeting of Oxysterol-Binding Protein-Like 6 Regulates Cholesterol Trafficking and Efflux. Arterioscler Thromb Vasc Biol. 2016 May; 36 (5): 942-951. doi: 10.1161/ATVBAHA.116.307282. |
| [19] | Rottiers V, Naar AM. MicroRNAs in metabolism and metabolic disorders. Nat Rev Mol Cell Biol 2012; 13: 239-250. |
| [20] | Jeon TI, Osborne TF. miRNA and cholesterol homeostasis. Biochim Biophys Acta. 2016 Dec; 1861 (12 Pt B): 2041-2046. doi: 10.1016/j.bbalip.2016.01.005. |
| [21] | Norata GD, Sala F, Catapano AL, Fernandez-Hernando C. MicroRNAs and lipoproteins: A connection beyond atherosclerosis? Atheroscle- rosis 2013; 227: 209-215. |
| [22] | Horie T, Ono K, Horiguchi M, Nishi H, Nakamura T, Nagao K, et al. MicroRNA-33 encoded by an intron of sterol regulatory element- binding protein 2 (Srebp2) regulates HDL in vivo. Proc Natl Acad Sci USA 2010; 107: 17321-17326. |
| [23] | Gerin I, Clerbaux LA, Haumont O, Lanthier N, Das AK, Burant CF, et al. Expression of miR-33 from an SREBP2 intron inhibits choles- terol export and fatty acid oxidation. J Biol Chem 2010; 285: 33652-33661. |
| [24] | Brown MS, Ye J, Goldstein JL. Medicine: HDL miR-ed down by SREBP introns. Science 2010; 328: 1495-1496. |
| [25] | Rui L. Energy metabolism in the liver. Compr Physiol. 2014 Jan; 4 (1): 177-97. doi: 10.1002/cphy.c130024. PMID: 24692138. |
| [26] | Kim JH, Lee JM, Kim JH, Kim KR. Fluvastatin activates sirtuin 6 to regulate sterol regulatory element-binding proteins and AMP-activated protein kinase in HepG2 cells. Biochem Biophys Res Commun. 2018 Sep 10; 503 (3): 1415-1421. doi: 10.1016/j.bbrc.2018.07.057. Epub 2018 Aug. |
| [27] | Gai Y, Li Y, Xu Z, Chen J Pseudoprotodioscin inhibits SREBPs and microRNA 33a/b levels and reduces the gene expression regarding the synthesis of cholesterol and triglycerides. Fitoterapia. 2019 Nov; 139: 104393. doi: 10.1016/j.fitote.2019.104393. |
| [28] | Horie T, Nishino T, Baba O, Kuwabara Y, Nakao T, Nishiga M, et al. MicroRNA-33b knock-in mice for an intron of sterol regulatory element-binding factor 1 (Srebf1) exhibit reduced HDL-C in vivo. Sci Rep 2014; 4: 5312, doi: 10.1038/srep05312. |
| [29] | Ono K, Horie T, Nishino T, Baba O, Kuwabara Y, Yokode M, Kita T, Kimura T. MicroRNA-33a/b in lipid metabolism-novel “thrifty” models. Circ J. 2015; 79 (2): 278-84. Doi 10.1253/circj.CJ-14-1252. |
APA Style
Alice Kiba Koumaré, Tegwinde Rebeca Compaoré, Fabienne Soudré, Raoul Karfo, Gnabôrou Rachid Konfé, et al. (2020). Role of microRNA-33a/b in Cholesterol Metabolism in Type 2 Diabetic Patients in Ouagadougou, Burkina Faso. Advances in Biochemistry, 7(4), 71-76. https://doi.org/10.11648/j.ab.20190704.11
ACS Style
Alice Kiba Koumaré; Tegwinde Rebeca Compaoré; Fabienne Soudré; Raoul Karfo; Gnabôrou Rachid Konfé, et al. Role of microRNA-33a/b in Cholesterol Metabolism in Type 2 Diabetic Patients in Ouagadougou, Burkina Faso. Adv. Biochem. 2020, 7(4), 71-76. doi: 10.11648/j.ab.20190704.11
AMA Style
Alice Kiba Koumaré, Tegwinde Rebeca Compaoré, Fabienne Soudré, Raoul Karfo, Gnabôrou Rachid Konfé, et al. Role of microRNA-33a/b in Cholesterol Metabolism in Type 2 Diabetic Patients in Ouagadougou, Burkina Faso. Adv Biochem. 2020;7(4):71-76. doi: 10.11648/j.ab.20190704.11
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ab.20190704.11,
author = {Alice Kiba Koumaré and Tegwinde Rebeca Compaoré and Fabienne Soudré and Raoul Karfo and Gnabôrou Rachid Konfé and Elie Kabré and Ignatius Baldeh and Jacques Simporé and Jean Sakandé},
title = {Role of microRNA-33a/b in Cholesterol Metabolism in Type 2 Diabetic Patients in Ouagadougou, Burkina Faso},
journal = {Advances in Biochemistry},
volume = {7},
number = {4},
pages = {71-76},
doi = {10.11648/j.ab.20190704.11},
url = {https://doi.org/10.11648/j.ab.20190704.11},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ab.20190704.11},
abstract = {MicroRNAs (miRNAs) are small endogenous RNAs approximately 22 nucleotides involved in the regulation of several cellular metabolisms including cholesterol metabolism. The objective of this study was to measure miRNAs 33a and 33b in type 2 diabetics to evaluate their impact on the lipids levels and prevalence of dyslipidemia. The study population profile was 45 subjects including 30 type 2 diabetic patients and 15 healthy controls. The lipids tests were performed using an automated Spintech 240 Biolis analyzer and the microRNAs (33a and 33b) by applied biosystems 7500 Fast Real Time PCR System using the TaqMan® MicroRNA Assay kit. The prevalence of dyslipidemia was higher in miRNA-33a positive subjects than miRNA-33a negative (p <0.0001). The prevalence of dyslipidemia was however not significant between miRNA-33b positive and miRNA-33b negative. A comparison between miRNA-33a positive and miRNA-33b positive showed a significant increase of dyslipidemia in miRNA-33a positive than in miRNA-33b positive subjects. The dyslipidemic types in miRNA-33a positive diabetics were 90% hypercholesterolemia, 88% LDLC increase and 83.33% HDLC decrease. The measurement of the HDLC subclasses showed 82.6% HDL2C decrease and 90.91% HDL3C increase. The HDL3C level increased in 100% of non hypertensive diabetics versus 46.67% in hypertensive diabetics (p=0.003). The increase of HDL3C was 90.9% in miRNA33a positive subjects versus 54.5% in miRNA33b positive subjects (p <0.006). The study therefore confirms the relationship between the presence of microRNAs 33a and increased cardiovascular risk. The results showed a role of microRNA-33a on the increase of HDL3C which has a weak atheroprotective role compared to HDL2C. This observation suggests that the research on drugs able to increase the HDLC level based on microRNA regulation should target the stimulation of HDL2C synthesis.},
year = {2020}
}
TY - JOUR T1 - Role of microRNA-33a/b in Cholesterol Metabolism in Type 2 Diabetic Patients in Ouagadougou, Burkina Faso AU - Alice Kiba Koumaré AU - Tegwinde Rebeca Compaoré AU - Fabienne Soudré AU - Raoul Karfo AU - Gnabôrou Rachid Konfé AU - Elie Kabré AU - Ignatius Baldeh AU - Jacques Simporé AU - Jean Sakandé Y1 - 2020/01/04 PY - 2020 N1 - https://doi.org/10.11648/j.ab.20190704.11 DO - 10.11648/j.ab.20190704.11 T2 - Advances in Biochemistry JF - Advances in Biochemistry JO - Advances in Biochemistry SP - 71 EP - 76 PB - Science Publishing Group SN - 2329-0862 UR - https://doi.org/10.11648/j.ab.20190704.11 AB - MicroRNAs (miRNAs) are small endogenous RNAs approximately 22 nucleotides involved in the regulation of several cellular metabolisms including cholesterol metabolism. The objective of this study was to measure miRNAs 33a and 33b in type 2 diabetics to evaluate their impact on the lipids levels and prevalence of dyslipidemia. The study population profile was 45 subjects including 30 type 2 diabetic patients and 15 healthy controls. The lipids tests were performed using an automated Spintech 240 Biolis analyzer and the microRNAs (33a and 33b) by applied biosystems 7500 Fast Real Time PCR System using the TaqMan® MicroRNA Assay kit. The prevalence of dyslipidemia was higher in miRNA-33a positive subjects than miRNA-33a negative (p <0.0001). The prevalence of dyslipidemia was however not significant between miRNA-33b positive and miRNA-33b negative. A comparison between miRNA-33a positive and miRNA-33b positive showed a significant increase of dyslipidemia in miRNA-33a positive than in miRNA-33b positive subjects. The dyslipidemic types in miRNA-33a positive diabetics were 90% hypercholesterolemia, 88% LDLC increase and 83.33% HDLC decrease. The measurement of the HDLC subclasses showed 82.6% HDL2C decrease and 90.91% HDL3C increase. The HDL3C level increased in 100% of non hypertensive diabetics versus 46.67% in hypertensive diabetics (p=0.003). The increase of HDL3C was 90.9% in miRNA33a positive subjects versus 54.5% in miRNA33b positive subjects (p <0.006). The study therefore confirms the relationship between the presence of microRNAs 33a and increased cardiovascular risk. The results showed a role of microRNA-33a on the increase of HDL3C which has a weak atheroprotective role compared to HDL2C. This observation suggests that the research on drugs able to increase the HDLC level based on microRNA regulation should target the stimulation of HDL2C synthesis. VL - 7 IS - 4 ER -
Information
Email: